Expanding the Stent-Graft Product Lineup and Entering the U.S. Market Through the Acquisition of Bolton Medical
First written in FY2017-Q3. 2 of 4 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2020-Q2.
2 other companies' latest entry also says "Advanced".
- FY2020-Q2AdvancedAnnual report
「In Japan, stent grafts for which the vascular business began direct sales」
The disclosure describes progress in the sales structure, with the Group beginning direct sales in Japan of stent grafts expanded through the acquisition of Bolton Medical and other measures. - FY2020-Q1AdvancedAnnual report
「In Japan, stent grafts, for which the vascular business began direct sales, and overseas, the WEB saccular intracranial aneurysm device in the neurovascular business, among others, are driving growth.」
The disclosure describes progress in the sales structure, with the Group beginning direct sales in Japan of stent grafts expanded through the acquisition of Bolton Medical and other measures. - FY2017AchievedAnnual report
「In the vascular business, we will seek a smooth integration with US-based Bolton Medical, Inc., whose acquisition was completed at the end of March 2017.」
The acquisition of Bolton Medical, Inc. and its affiliated companies was completed at the end of March 2017, and the Group moved into the phase of advancing integration in the following fiscal year. - FY2017-Q3First statedAnnual report
「Through this acquisition, we will expand our stent graft product lineup and secure an opportunity to enter the US, the largest market, thereby driving further growth in the vascular business.」
The Group agreed to acquire Bolton Medical, Inc., which manufactures and sells thoracic and abdominal stent grafts, and its related businesses. The business combination was scheduled for spring 2017, with expansion of the product lineup and entry into the US market identified as growth drivers.